In the last years, the interest for nano- and micro-structured materials in biology and medicine is enormously increased. In particular, the use of nano- and micro-particles (NPs) for delivery drugs and contrast agents in vivo became attractive, due to their potential applicative use in diagnosis and therapy of widespread diseases such as tumors and neurodegenerative diseases. In spite of this big scientific and economic interest, only a few products based on NPs technologies have come to industrial production and distribution. The partial failure is due to complex reasons, such as the difficulty of designing NPs for biomedical applications with advanced features of biocompatibility, biomimicry and targeting. Only a few of the NPs already existing can be used in vivo, mainly because of their scarce targeting specificity and/or biocompatibility. The aim of our work is the preparation of new nanoparticles for drug delivery to tumors and brain, with improved feature of biocompatibility/biomimicry and targeting specificity, constituted by a core of poly-lactic-co-glycolic acid (PLGA) with a corona of poly(amidoamine) (PAA).

Preparation of new PLGA/PAA nanoparticles for biomedical applications with improved biocompatibility / E. Cazzaniga, A.G. Manfredi, F. Mantegazza, R. Ziano, M. Masserini, I. Rivolta, A. Panariti, G. Sancini, I. Cambianica, A. Brambilla, E. Ranucci. ((Intervento presentato al 7. convegno International Conference on Biomedical Applications of Nanotechnology tenutosi a Berlin nel 2010.

Preparation of new PLGA/PAA nanoparticles for biomedical applications with improved biocompatibility

A.G. Manfredi
Secondo
;
E. Ranucci
Ultimo
2010

Abstract

In the last years, the interest for nano- and micro-structured materials in biology and medicine is enormously increased. In particular, the use of nano- and micro-particles (NPs) for delivery drugs and contrast agents in vivo became attractive, due to their potential applicative use in diagnosis and therapy of widespread diseases such as tumors and neurodegenerative diseases. In spite of this big scientific and economic interest, only a few products based on NPs technologies have come to industrial production and distribution. The partial failure is due to complex reasons, such as the difficulty of designing NPs for biomedical applications with advanced features of biocompatibility, biomimicry and targeting. Only a few of the NPs already existing can be used in vivo, mainly because of their scarce targeting specificity and/or biocompatibility. The aim of our work is the preparation of new nanoparticles for drug delivery to tumors and brain, with improved feature of biocompatibility/biomimicry and targeting specificity, constituted by a core of poly-lactic-co-glycolic acid (PLGA) with a corona of poly(amidoamine) (PAA).
2-dic-2010
Settore CHIM/04 - Chimica Industriale
Settore BIO/09 - Fisiologia
Settore BIO/10 - Biochimica
Preparation of new PLGA/PAA nanoparticles for biomedical applications with improved biocompatibility / E. Cazzaniga, A.G. Manfredi, F. Mantegazza, R. Ziano, M. Masserini, I. Rivolta, A. Panariti, G. Sancini, I. Cambianica, A. Brambilla, E. Ranucci. ((Intervento presentato al 7. convegno International Conference on Biomedical Applications of Nanotechnology tenutosi a Berlin nel 2010.
Conference Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/162797
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact